Search results
Results from the WOW.Com Content Network
Citalopram was approved for medical use in the United States in 1998. [7] It is on the World Health Organization's List of Essential Medicines. [11] It is available as a generic medication. [12] In 2022, it was the 40th most commonly prescribed medication in the United States, with more than 15 million prescriptions. [13] [14]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
Paroxetine was the first drug to be approved for social anxiety disorder and it is considered effective for this disorder; sertraline and fluvoxamine were later approved for it as well. Escitalopram and citalopram are used off-label with acceptable efficacy, while fluoxetine is not considered to be effective for this disorder. [22]
Citalopram. As a generic and under the brand name Celexa, citalopram is prescribed off-label to treat anxiety disorders, including social anxiety disorder, panic disorder and generalized anxiety ...
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. . Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among oth
Find Out: How Long You Could Last on Nothing but Social Security in 50 Major Cities. Whether We’ll See Reduced Benefits Depends on Both Trump and Congress.